Status:
COMPLETED
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
Lead Sponsor:
AstraZeneca
Conditions:
Hypereosinophilic Syndrome (HES)
Eligibility:
All Genders
Brief Summary
The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
Detailed Description
Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden.
Eligibility Criteria
Inclusion
- Diagnosis record of HES (ICD-10-CM D72.11) anytime during 01 October 2020 to 30 June 2023
- At least 12 months of patient insurance record prior to first HES record.
Exclusion
- Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES).
- History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES)
- History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES)
- History of helminthiasis or use of anthelmintic medication (to exclude reactive HES)
- History of autoimmune disease (to exclude reactive HES)
- History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)
Key Trial Info
Start Date :
December 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 26 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06172751
Start Date
December 15 2023
End Date
April 26 2024
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cambridge, Massachusetts, United States, 02140